In an independent study, anti-CTLA4 Ab was found to enhance the anti-tumor effect by altering the ratio of effector T cell (Teff) to regulatory T cell (Treg) in the tumor microenvironment (TME) in human Fc-gamma receptors (FcγRs)-treated mouse models inoculated with MCA205 cells [10]. This evidence concerns the gene CTLA4 and neoplasm.